Physician profile
Syed Amiry
NPI 1396815031
$26,148.71
in general payments reported to CMS, 2019-2025
23 companies · $641 in 2025
The $641 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $131 · 2021: $8,956 · 2022: $14K · 2023: $560 · 2024: $752 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23,110.72 | 2019-2022 | |
| Galderma Laboratories, L.P. | $685.56 | 2019-2024 | |
| Abbvie INC. | $361.13 | 2020-2025 | Botox, Rinvoq |
| Revance Therapeutics, INC. | $317.56 | 2024-2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $275.33 | 2021-2025 | |
| Leo Pharma INC. | $169.71 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $169.19 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $147.89 | 2024-2025 | |
| Merz North America, INC. | $143.41 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $110.04 | 2023-2024 | Sotyktu |
| Incyte Corporation | $98.86 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $92.02 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.54 | 2020-2025 | Jublia, Cabtreo, Arazlo |
| Sun Pharmaceutical Industries INC. | $81.83 | 2022-2024 | Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $54.53 | 2023 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $53.40 | 2025 | |
| Janssen Biotech, INC. | $41.43 | 2024-2025 | Tremfya |
| Ucb, INC. | $37.89 | 2025 | Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $28.30 | 2022 | |
| Amgen INC. | $27.64 | 2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.98 | 2022 | |
| Almirall LLC | $18.17 | 2022 | |
| Journey Medical Corporation | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Amiry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.